Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence

Accumulation of meningeal lymphocytes correlates with white matter lesion activity in progressive MS

(2022) Shanzeh M. Ahmed et al.   JCI Insight

Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson’s Disease Pathogenesis: A Narrative Review

(2022) Efthalia Angelopoulou et al.   Brain Sciences

Repurposing ibudilast to mitigate Alzheimer’s disease by targeting inflammation

(2022) Giovanni Oliveros et al.   BRAIN

Solving neurodegeneration: common mechanisms and strategies for new treatments

(2022) Lauren K. Wareham et al.   Molecular Neurodegeneration

Lysosomal dysfunction in neurodegeneration: emerging concepts and methods

(2022) Vinod Udayar et al.   TRENDS IN NEUROSCIENCES

Common Fatal Neurodegenerative Diseases Revisited: Beyond Age, Comorbidities, and Devastating Terminal Neuropathology There Is Hope With Prevention

(2022) Lilian Calderón-Garcidueñas   Frontiers in Neurology

An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022

(2022) Letizia Crocetti et al.   MOLECULES

Neuroprotective effects of ibudilast against tacrolimus induced neurotoxicity

(2022) Wei Zhang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype

(2021) Andrew D. Goodman et al.   Annals of Clinical and Translational Neurology

Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer’s Disease

(2021) Jonathan D. Drake et al.   JOURNAL OF ALZHEIMERS DISEASE

Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis

(2021) Robert J Fox et al.   Multiple Sclerosis Journal

Therapeutic news in ALS

(2021) P. Corcia et al.   REVUE NEUROLOGIQUE

APOE Genotype and Alzheimer’s Disease: The Influence of Lifestyle and Environmental Factors

(2021) Efthalia Angelopoulou et al.   ACS Chemical Neuroscience

Storage of Mutant Human SOD1 in Non-Neural Cells from the Type-1 Amyotrophic Lateral Sclerosis ratG93A Model Correlated with the Lysosomes’ Dysfunction

(2021) Ilaria Bicchi et al.   Biomedicines

MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design

(2021) Björn Oskarsson et al.   Neurodegenerative Disease Management

Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington’s disease

(2020) Efthalia Angelopoulou et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting

(2020) Yam Nath Paudel et al.   Cells

Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: The new molecular mechanism of ibudilast and its implication for neuroprotective therapy

(2020) Yanming Chen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer’s disease

(2020) Elham Nasiri et al.   MOLECULAR MEDICINE

Tracing the History of the Human Translocator Protein to Recent Neurodegenerative and Psychiatric Imaging

(2020) Olivia M. Downer et al.   ACS Chemical Neuroscience

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

(2020) Tiantian Guo et al.   Molecular Neurodegeneration

Implication of HMGB1 signaling pathways in Amyotrophic lateral sclerosis (ALS): From molecular mechanisms to pre-clinical results

(2020) Yam Nath Paudel et al.   PHARMACOLOGICAL RESEARCH

Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson’s disease: Potential clinical and therapeutic implications

(2020) Efthalia Angelopoulou et al.   PHARMACOLOGICAL RESEARCH

Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome

(2020) Lien D. Nguyen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ibudilast, a Phosphodiesterase Inhibitor and Toll-Like Receptor-4 Antagonist, Improves Hemorrhagic Shock and Reperfusion-Induced Left Ventricular Dysfunction by Reducing Myocardial Tumor Necrosis Factor α

(2020) Nan-Chun Wu et al.   TRANSPLANTATION PROCEEDINGS

Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis

(2020) Robert A Bermel et al.   Multiple Sclerosis Journal

Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study

(2020) Robert T. Naismith et al.   NEUROLOGY

Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes

(2020) Hyuk Sung Kwon et al.   Translational Neurodegeneration

The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?

(2019) Rudolf C Hergesheimer et al.   BRAIN

Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP+-induced oxidative insult

(2019) Jiahong Zhong et al.   FREE RADICAL BIOLOGY AND MEDICINE

Protection from amyloid β peptide-induced memory, biochemical and morphological deficits by a phosphodiesterase-4D (PDE4D) allosteric inhibitor

(2019) Su-Ying Cui et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease

(2019) Efthalia Angelopoulou et al.   PARKINSONISM & RELATED DISORDERS

High mobility group box 1 (HMGB1) protein in Multiple Sclerosis (MS): Mechanisms and therapeutic potential

(2019) Yam Nath Paudel et al.   LIFE SCIENCES

Deep gray matter volume loss drives disability worsening in multiple sclerosis

(2018) Arman Eshaghi et al.   ANNALS OF NEUROLOGY

Integrated MRI and [11 C]-PBR28 PET Imaging in Amyotrophic Lateral sclerosis

(2018) Mohamad J. Alshikho et al.   ANNALS OF NEUROLOGY

Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline

(2018) Masahide Fujita et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP + -induced decline of mitochondrial membrane potential and oxidative stress

(2018) Jiahong Zhong et al.   Redox Biology

Aging and the immune system: An overview

(2018) Amir A. Sadighi Akha   JOURNAL OF IMMUNOLOGICAL METHODS

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

(2018) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease

(2017) Jos Prickaerts et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications

(2017) Jia Liu et al.   Frontiers in Immunology

The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson’s disease

(2017) Joanna Schwenkgrub et al.   PLoS One

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis

(2016) Robert J. Fox et al.   Contemporary Clinical Trials

Wolfram Syndrome: Diagnosis, Management, and Treatment

(2016) Fumihiko Urano   Current Diabetes Reports

The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling

(2016) Jorge L. Cueva Vargas et al.   NEUROBIOLOGY OF DISEASE

Ibudilast attenuates expression of behavioral sensitization to cocaine in male and female rats

(2016) Ryan S. Poland et al.   NEUROPHARMACOLOGY

Cilostazol Upregulates Autophagy via SIRT1 Activation: Reducing Amyloid-β Peptide and APP-CTFβ Levels in Neuronal Cells

(2015) Hye Rin Lee et al.   PLoS One

Neuronal Matrix Metalloproteinase-9 Is a Determinant of Selective Neurodegeneration

(2014) Artem Kaplan et al.   NEURON

Improved Long-Term Memory via Enhancing cGMP-PKG Signaling Requires cAMP-PKA Signaling

(2014) Eva Bollen et al.   NEUROPSYCHOPHARMACOLOGY

Pretreatment with antiasthmatic drug ibudilast ameliorates Aβ1–42-induced memory impairment and neurotoxicity in mice

(2014) Hao Wang et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid

(2014) Takakuni Maki et al.   Annals of Clinical and Translational Neurology

SOD1 Aggregation and ALS: Role of Metallation States and Disulfide Status

(2013) Yuewei Sheng et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders

(2013) Sorabh Sharma et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Multiple sclerosis is primarily a neurodegenerative disease

(2013) Abhijit Chaudhuri   JOURNAL OF NEURAL TRANSMISSION

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine - searching for the connections

(2012) Wojciech Danysz et al.   BRITISH JOURNAL OF PHARMACOLOGY

Phosphodiesterases in neurodegenerative disorders

(2012) Eva Bollen et al.   IUBMB LIFE

Inhibition of Paclitaxel-induced Decreases in Calcium Signaling

(2012) Jennifer H. Benbow et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Microglial Activation Correlates with Disease Progression and Upper Motor Neuron Clinical Symptoms in Amyotrophic Lateral Sclerosis

(2012) Johannes Brettschneider et al.   PLoS One

Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation

(2011) Sun Haeng Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration

(2011) Massimiliano M. Corsi et al.   BIOGERONTOLOGY

Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory activity, protects against ischemic brain injury in rats

(2011) Joo-Yong Lee et al.   BRAIN RESEARCH

Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

(2011) Thérèse Keravis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Multiple Sclerosis: Pathogenesis and Treatment

(2011) Ingrid Loma et al.   Current Neuropharmacology

The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats

(2011) Chuang Wang et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: Prospective clinical and MRI follow-up study

(2011) Sanna Hagman et al.   JOURNAL OF NEUROIMMUNOLOGY

PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: A key step in parkinsonism physiopathology

(2011) M. Giorgi et al.   NEUROBIOLOGY OF DISEASE

Ibudilast, a Pharmacologic Phosphodiesterase Inhibitor, Prevents Human Immunodeficiency Virus-1 Tat-Mediated Activation of Microglial Cells

(2011) Michelle Kiebala et al.   PLoS One

Cilostazol prevents amyloid β peptide25-35-induced memory impairment and oxidative stress in mice

(2010) Masayuki Hiramatsu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant?

(2010) F. Barkhof et al.   NEUROLOGY

Ibudilast Inhibits Cerebral Aneurysms by Down-Regulating Inflammation-Related Molecules in the Vascular Wall of Rats

(2010) Kenji Yagi et al.   NEUROSURGERY

Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease

(2010) Carmela Giampà et al.   PLoS One

Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease

(2009) P Rolan et al.   EXPERT OPINION ON PHARMACOTHERAPY

Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood—brain barrier disruption in multiple sclerosis

(2009) Bibiana Bielekova et al.   Multiple Sclerosis Journal

Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system

(2009) Xiaoju Wang et al.   NEUROSCIENCE LETTERS

Cross-species comparisons of the pharmacokinetics of ibudilast

(2009) L. M. Sanftner et al.   XENOBIOTICA

Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses

(2008) Paul Rolan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms

(2008) M. Giorgi et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Pivotal Advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis

(2008) Åsa Andersson et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV

(2007) Lichuan Yang et al.   EXPERIMENTAL NEUROLOGY